Patent ID: 11925641
Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 18:
19. A method of treating a malignant condition in a subject in need thereof, comprising administering to the subject the compound according to claim 17, or a stereoisomer or pharmaceutically acceptable salt thereof, wherein the malignant condition is selected from hematological malignancies, multiple myeloma, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), melanoma, ER-negative breast cancer, diffuse large B cell lymphoma (DLBCL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), head and neck cancer, breast cancer, prostate cancer, and colorectal cancer.